Similar articles for PMID: 20956338

Year	Number of Results
2005	2
2006	1
2007	2
2008	5
2009	4
2010	8
2011	3
2012	5
2013	7
2014	15
2015	11
2016	4
2017	11
2018	17
2019	8
2020	4
2021	3
2022	2
2023	1
2024	0

1

Cutting edge: A critical functional role for IL-23 in psoriasis.

Tonel G, Conrad C, Laggner U, Di Meglio P, Grys K, McClanahan TK, Blumenschein WM, Qin JZ, Xin H, Oldham E, Kastelein R, Nickoloff BJ, Nestle FO. Tonel G, et al. J Immunol. 2010 Nov 15;185(10):5688-91. doi: 10.4049/jimmunol.1001538. Epub 2010 Oct 18. J Immunol. 2010. PMID: 20956338 Free PMC article.

2

A plaidoyer for the use of human skin xenotransplant mouse models in preclinical psoriasis research.

Gilhar A, Reich K, Keren A, Paus R. Gilhar A, et al. J Eur Acad Dermatol Venereol. 2023 Mar;37(3):e406-e409. doi: 10.1111/jdv.18644. Epub 2022 Oct 20. J Eur Acad Dermatol Venereol. 2023. PMID: 36227126 No abstract available.

3

Treatment strategies, management of comorbidities, and the role of IL-23 inhibitors in moderate to severe psoriasis.

Bagel J. Bagel J. Am J Manag Care. 2021 Jun;27(10 Suppl):S203-S208. doi: 10.37765/ajmc.2021.88675. Am J Manag Care. 2021. PMID: 34110117 Free article.

4

Probing the binding of interleukin-23 to individual receptor components and the IL-23 heteromeric receptor complex in living cells using NanoBRET.

Lay CS, Bridges A, Goulding J, Briddon SJ, Soloviev Z, Craggs PD, Hill SJ. Lay CS, et al. Cell Chem Biol. 2022 Jan 20;29(1):19-29.e6. doi: 10.1016/j.chembiol.2021.05.002. Epub 2021 May 25. Cell Chem Biol. 2022. PMID: 34038748 Free PMC article.

5

Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.

Zhang M, Li N, Cai R, Gu J, Xie F, Wei H, Lu C, Wu D. Zhang M, et al. Phytother Res. 2021 Aug;35(8):4526-4537. doi: 10.1002/ptr.7155. Epub 2021 May 18. Phytother Res. 2021. PMID: 34008239

6

Risk for deep fungal infections during IL-17 and IL-23 inhibitor therapy for psoriasis.

Lee MP, Wu KK, Lee EB, Wu JJ. Lee MP, et al. Cutis. 2020 Oct;106(4):199-205. doi: 10.12788/cutis.0088. Cutis. 2020. PMID: 33186421 Review.

7

IBI112, a selective anti-IL23p19 monoclonal antibody, displays high efficacy in IL-23-induced psoriasiform dermatitis.

Li L, Wu Z, Wu M, Qiu X, Wu Y, Kuang Z, Wang L, Sun T, Liu Y, Yi S, Jing H, Zhou S, Chen B, Wu D, Wu W, Liu J. Li L, et al. Int Immunopharmacol. 2020 Dec;89(Pt B):107008. doi: 10.1016/j.intimp.2020.107008. Epub 2020 Oct 15. Int Immunopharmacol. 2020. PMID: 33069927

8

COVID-19 infection on IL-23 inhibition.

Wang CJ, Truong AK. Wang CJ, et al. Dermatol Ther. 2020 Nov;33(6):e13893. doi: 10.1111/dth.13893. Epub 2020 Jul 14. Dermatol Ther. 2020. PMID: 32584451 Free PMC article. No abstract available.

9

Guselkumab in the treatment of moderate-to-severe plaque psoriasis.

López-Sánchez C, Puig L. López-Sánchez C, et al. Immunotherapy. 2020 Apr;12(6):355-371. doi: 10.2217/imt-2020-0040. Epub 2020 Apr 21. Immunotherapy. 2020. PMID: 32314622 Review.

10

The safety of anti-interleukins monoclonal antibodies for the treatment of psoriasis.

D'Adamio S, Silvaggio D, Lombardo P, Bianchi L, Talamonti M, Galluzzo M. D'Adamio S, et al. Expert Opin Drug Saf. 2019 Nov;18(11):1031-1041. doi: 10.1080/14740338.2019.1663168. Epub 2019 Sep 11. Expert Opin Drug Saf. 2019. PMID: 31479282 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

97 results

Results by year